Galloflavin / LDH Cancer Research Results

Galloflavin is unusually clean mechanistically:
-LDH-A inhibition is the primary molecular target
-Everything else (↓ lactate, NAD⁺ stress, ROS, mitochondrial dependence) is downstream
-Apoptosis and tumor suppression are consequences, not drivers
This makes galloflavin one of the best-defined Warburg-effect inhibitors.

Not use if antitumor effect extends to in vivo?

Galloflavin — a synthetic polyphenolic small molecule and non-substrate-competitive inhibitor of human lactate dehydrogenase A and B. It is classified as an experimental metabolic anticancer agent and Warburg-effect inhibitor; the standard abbreviation is GF. Galloflavin, CAS 568-80-9, was originally characterized as an oxidation-derived dimeric product related to gallic acid rather than as a clinically established plant flavonoid. It remains a research compound with no approved therapeutic indication.

Primary mechanisms (ranked):

1. Direct inhibition of LDH-A and LDH-B, preferentially through binding to the free enzyme.
2. Suppression of pyruvate-to-lactate conversion, aerobic glycolysis, lactate secretion and glycolysis-dependent ATP production.
3. Disruption of NADH/NAD⁺ redox recycling and induction of metabolic stress in highly glycolytic cancer cells.
4. Induction of apoptosis through context-dependent mitochondrial, caspase and survival-signalling changes.
5. Suppression of MYC-associated metabolic and proliferative signalling in susceptible cancer models.
6. Reduction of inflammation-associated epithelial–mesenchymal transition, migration and invasive behaviour through decreased lactate production.
7. Inhibition of noncanonical LDH-A binding to single-stranded DNA and suppression of cellular RNA synthesis.
8. Context-dependent elevation of ROS, mitochondrial DNA damage and oxidative stress downstream of metabolic disruption.
9. Context-dependent inhibition of NLRP3-associated inflammatory and malignant signalling in colorectal cancer models.

Bioavailability / PK relevance: No validated human pharmacokinetic, oral-bioavailability or therapeutic-exposure data are available. Galloflavin has been described as having poor physicochemical and drug-development properties, prompting development of galloflavin mimetics and alternative LDH inhibitors. Systemic exposure, metabolic stability, tissue distribution, protein binding and dose-limiting toxicity remain insufficiently characterized.

In-vitro vs systemic exposure relevance: Most anticancer studies use approximately 10–100 µM galloflavin, commonly around 25–50 µM over 24–72 hours. Whether these concentrations can be safely and continuously achieved in human tumors is unknown. Consequently, direct translation of cell-culture efficacy to oral or systemic treatment is not currently justified.

Clinical evidence status: Preclinical only. Evidence consists predominantly of enzyme assays and cultured cancer-cell studies, including breast, lymphoma, endometrial, pancreatic and colorectal models. Some animal or mechanistic studies may exist, but there is no established human cancer trial, approved formulation, clinical dose, demonstrated response rate or regulatory authorization for galloflavin.

Safety and interpretation: Galloflavin inhibits both LDH-A and LDH-B rather than being strictly LDH-A selective. Because LDH is required in normal erythrocytes, skeletal muscle, heart and other tissues during high glycolytic demand, systemic LDH inhibition could produce on-target toxicity. Normal-cell selectivity, hemolytic risk, exercise intolerance, hepatic effects, drug interactions and chronic safety have not been adequately established.

Galloflavin Mechanistic Profile

P: 0–30 min    R: 30 min–3 hr    G: >3 hr